Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia

摘要: Main mechanisms involved in the development of chemotherapy-induced anemia are direct bone marrow damage and renal impairment with a secondary deficient production erythropoietin. The first mechanism is induced by almost all cytotoxic drugs whilst second one has been demonstrated cisplatin treatment. NSCLC patients generally treated platinum-based chemotherapy then both which can be, as consequence, more frequent severe compared to other cancer patients. Chemotherapy regimens such MVP (mitomycin, vindesine, platin), cisplatin-etoposide teniposide induce grade ≥ 2 64%, 46% 83% patients, respectively, 3-4 occurring 29%, 15% 24% New also associated high incidence anemia. Carboplatin- paclitaxel induces 34% 30% need blood transfusions. Similarly, 33% cisplatin-gemcitabine require Erythropoietin able correct nearly 60%-80% receiving 40% without platinum compounds, leading reduction transfusion requirement. Moreover, erythropoietin prevent Due anemia, may represent an important tool supportive care use mainly limited economic cost efforts should be made identify subset whom this therapy cost-effective. Patient disease characteristics, factors predicting probability transfused well response useful selecting likely benefit from therapy.